FDA Approves Dupixent to Treat Eczema

Share this content:
FDA Approves Dupixent to Treat Eczema
FDA Approves Dupixent to Treat Eczema

WEDNESDAY, March 29, 2017 (HealthDay News) -- Dupixent (dupilumab) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe eczema that isn't well controlled by topical medication.

The active ingredient in Dupixent is an antibody (dupilumab) that binds to a protein (interleukin-4 receptor alpha subunit) that causes inflammation, and is administered subcutaneously. Its effectiveness was evaluated in clinical studies involving 2,119 patients for whom topical medication hadn't worked. Overall, participants who received Dupixent achieved clear or almost clear skin and a reduction in itch after 16 weeks of treatment.

The most common side effects included injection-site reactions, cold sores, and eye inflammation. More serious adverse effects included severe allergic reactions, conjunctivitis, and keratitis.

"FDA's approval of Dupixent demonstrates our commitment to approving new and innovative therapies for patients with skin disease," Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research, said in a statement. "Eczema can cause significant skin irritation and discomfort for patients, so it is important to have a variety of treatment options available to patients, including those patients whose disease is not controlled by topical therapies."

The FDA granted approval of Dupixent to Regeneron Pharmaceuticals.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Hospitals Vary Widely in Moving Stroke Patients to Comfort Care

Hospitals Vary Widely in Moving Stroke Patients to ...

Doctors more apt to suggest it sooner for older, white, female, and uninsured patients

Peri-Op IV Acetaminophen May Reduce Post-Op Pain in Sinus Sx

Peri-Op IV Acetaminophen May Reduce Post-Op Pain in ...

Reduction in immediate postoperative pain after endoscopic sinus surgery, but results inconclusive

Location of Body Fat Can Indicate Obesity-Related Cancer Risk

Location of Body Fat Can Indicate Obesity-Related Cancer ...

Where fat is carried is as strong a predictor as BMI, researchers suggest

is free, fast, and customized just for you!

Already a member?

Sign In Now »